Transcriptomic analysis reveals an immune-based classification in malignant pleural mesothelioma, indicating distinct patient prognosis and immunotherapy benefit.
This study identifies a novel immune-based signature with potential clinical relevance based on TH2 and TC levels, unveiling a fraction of patients with MPM with better prognosis and who might benefit from immune-based therapies. Molecular specificities of the different groups might be used to tailor specific potential therapies in the future.
No takes yet. Share an insight, caveat, or question.
Alay et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: